Multiple doses of IPTi proposal: a lifesaving high yield intervention

The MULTIPLY project aims to maximise the delivery and uptake of Intermittent Preventive Treatment in infants (IPTi) with sulfadoxine-pirymethamine (SP), to achieve full potential and effectiveness of this intervention against malaria. Through this implementation, capacity will be built and fundamental programmatic issues to achieving effectiveness will be assessed, including:IPTi operational feasibility and acceptability; impact on health services integration, i.e. on Expanded Program on Immunization (EPI) immunisations and vitamin A administration coverage; the cost and cost-effectiveness of IPTi delivery including through the outreach EPI platform; the impact on malaria incidence, anaemia, overall mortality, SP resistance development and the safety of the intervention.MULTIPLY includes public and private European and African institutions. Research partners from Mozambique, Sierra Leone and Togo in selected country districts will conduct the implementation of IPTi-SP at health facilities and EPI mobile-outreach clinics using a paediatric dispersible formulation of SP, alongside routine vaccinations and vitamin A supplementation. Children will receive up to a maximum of 6 doses of IPTi-SP in the first two years of life. The aim of the SP drug resistance sub-study is to generate evidence on the development of parasite resistance to SP at the community level during the project period that informs policy recommendations.